Literature DB >> 11459123

Possible roles of cardiac chymase after myocardial infarction in hamster hearts.

D Jin1, S Takai, M Yamada, M Sakaguchi, Y Yao, M Miyazaki.   

Abstract

The significance of cardiac chymase after myocardial infarction (MI) was evaluated using a hamster model of MI. At 1, 3, 7, 14, 28 and 56 days after MI, tissues were removed for measurements of angiotensin-converting enzyme (ACE) and chymase activities. The mean infarct size 3 days after left coronary artery ligation was 47.3 +/- 5.9% of the left ventricle circumference. The ratio of left ventricle weight to body weight was significantly increased from 3 days after MI. The level of plasma renin activity in the MI hamsters was significantly increased at the early phase of MI (1-3 days), while no significant changes in plasma ACE activity were observed. The ACE activity in the infarcted left ventricle was significantly increased starting from 3 days after MI and this increase was sustained up to 28 days. The chymase activity in the infarcted left ventricle was significantly increased starting from 1 day after MI and this increase was sustained up to 56 days. The number of chymase-positive mast cells in the infarcted left ventricle was significantly higher than in the sham group 3 and 7 days after operation. Treatment with an angiotensin (Ang) II type 1 receptor antagonist (candesartan cilexetil, 10 mg/kg per day) starting 3 days before the induction of MI significantly reduced the mortality rate during 14 days of observation following MI, whereas treatment with an ACE inhibitor (lisinopril, 20 mg/kg per day) did not. A significant improvement in hemodynamics (maximal negative and positive rates of pressure development, left ventricular systolic pressure and end-diastolic pressure, mean arterial blood pressure) was observed by the treatment with candesartan cilexetil, but not with lisinopril, 3 and 14 days after MI. These results suggested that Ang II produced by chymase may participate in the pathophysiologic state after MI in hamsters.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11459123     DOI: 10.1254/jjp.86.203

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  16 in total

Review 1.  Cardiac mast cells: the centrepiece in adverse myocardial remodelling.

Authors:  Scott P Levick; Giselle C Meléndez; Eric Plante; Jennifer L McLarty; Gregory L Brower; Joseph S Janicki
Journal:  Cardiovasc Res       Date:  2010-08-24       Impact factor: 10.787

2.  Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents.

Authors:  Chih-Chang Wei; Naoki Hase; Yukiko Inoue; Eddie W Bradley; Eiji Yahiro; Ming Li; Nawazish Naqvi; Pamela C Powell; Ke Shi; Yoshimasa Takahashi; Keijiro Saku; Hidenori Urata; Louis J Dell'italia; Ahsan Husain
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

3.  ACE inhibitors to block MMP-9 activity: new functions for old inhibitors.

Authors:  Yufang Jin; Hai-Chao Han; Merry L Lindsey
Journal:  J Mol Cell Cardiol       Date:  2007-09-12       Impact factor: 5.000

4.  Possible roles of mast cell-derived chymase for skin rejuvenation.

Authors:  Nobuyuki Amano; Shinji Takai; Denan Jin; Koichi Ueda; Mizuo Miyazaki
Journal:  Lasers Med Sci       Date:  2008-04-12       Impact factor: 3.161

Review 5.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

6.  The emerging prominence of the cardiac mast cell as a potent mediator of adverse myocardial remodeling.

Authors:  Joseph S Janicki; Gregory L Brower; Scott P Levick
Journal:  Methods Mol Biol       Date:  2015

Review 7.  Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.

Authors:  Aina He; Guo-Ping Shi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 8.  Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

Authors:  Sarfaraz Ahmad; Carlos M Ferrario
Journal:  Expert Opin Ther Pat       Date:  2018-10-10       Impact factor: 6.674

9.  Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin-dependent pathway in hamster sponge granulomas.

Authors:  Michiko Muramatsu; Mayumi Yamada; Shinji Takai; Mizuo Miyazaki
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

10.  Mast cells: pivotal players in cardiovascular diseases.

Authors:  Ilze Bot; Theo J C van Berkel; Erik A L Biessen
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.